347 results on '"McMullen, Julie R."'
Search Results
2. Research Priorities for Atrial Fibrillation in Australia: A Statement From the Australian Cardiovascular Alliance Clinical Arrhythmia Theme
3. Estrogen receptor alpha deficiency in cardiomyocytes reprograms the heart-derived extracellular vesicle proteome and induces obesity in female mice
4. Distinct functional and molecular profiles between physiological and pathological atrial enlargement offer potential new therapeutic opportunities for atrial fibrillation.
5. IGF1–PI3K-induced physiological cardiac hypertrophy: Implications for new heart failure therapies, biomarkers, and predicting cardiotoxicity
6. Loss of the long non-coding RNA OIP5-AS1 exacerbates heart failure in a sex-specific manner
7. Prevention of Pathological Atrial Remodeling and Atrial Fibrillation: JACC State-of-the-Art Review
8. Exercise training reveals micro-RNAs associated with improved cardiac function and electrophysiology in rats with heart failure after myocardial infarction
9. Clusterin is regulated by IGF1–PI3K signaling in the heart: implications for biomarker and drug target discovery, and cardiotoxicity
10. Adeno-Associated Virus Gene Therapy: Translational Progress and Future Prospects in the Treatment of Heart Failure
11. Standing up to the cardiometabolic consequences of hematological cancers
12. Phosphoinositide 3-Kinase(p110α) Plays a Critical Role for the Induction of Physiological, but Not Pathological, Cardiac Hypertrophy
13. Cardiovascular magnetic resonance imaging for sequential assessment of cardiac fibrosis in mice: technical advancements and reverse translation.
14. Deletion of the muscle enriched lncRNA Oip5os1 induces atrial dysfunction in male mice with diabetes.
15. Molecular Aspects of Exercise-induced Cardiac Remodeling
16. PP2A negatively regulates the hypertrophic response by dephosphorylating HDAC2 S394 in the heart
17. Expressing an inhibitor of PLCβ1b sustains contractile function following pressure overload
18. Mechanisms responsible for increased circulating levels of galectin-3 in cardiomyopathy and heart failure
19. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets
20. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function
21. Author Correction: PP2A negatively regulates the hypertrophic response by dephosphorylating HDAC2 S394 in the heart
22. A MicroRNA Guide for Clinicians and Basic Scientists: Background and Experimental Techniques
23. The yin and yang of adaptive and maladaptive processes in heart failure
24. Protective Effects of Exercise and Phosphoinositide 3-Kinase(p110α) Signaling in Dilated and Hypertrophic Cardiomyopathy
25. Tissue-specific expression of Cas9 has no impact on whole-body metabolism in four transgenic mouse lines
26. Gata4 Is Required for Maintenance of Postnatal Cardiac Function and Protection from Pressure Overload-Induced Heart Failure
27. Editorial overview: Exercise-induced cardiac protection: Mechanisms and clinical implications
28. Inhibition of miR-154 Protects Against Cardiac Dysfunction and Fibrosis in a Mouse Model of Pressure Overload
29. Therapeutic targeting of oxidative stress with coenzyme Q10 counteracts exaggerated diabetic cardiomyopathy in a mouse model of diabetes with diminished PI3K(p110α) signaling
30. Letʼs keep running… exercise, basic science and the knowledge gaps
31. In Vivo Inhibition of miR-34a Modestly Limits Cardiac Enlargement and Fibrosis in a Mouse Model with Established Type 1 Diabetes-Induced Cardiomyopathy, but Does Not Improve Diastolic Function.
32. MicroRNAs differentially regulated in cardiac and skeletal muscle in health and disease: Potential drug targets?
33. Diabetic cardiomyopathy: Mechanisms and new treatment strategies targeting antioxidant signaling pathways
34. The therapeutic potential of miRNAs regulated in settings of physiological cardiac hypertrophy
35. Heritable pathologic cardiac hypertrophy in adulthood is preceded by neonatal cardiac growth restriction
36. Phosphoinositide 3-kinase Akt signaling pathway interacts with protein kinase C[beta]2 in the regulation of physiologic developmental hypertrophy and heart function
37. Fine-Tuning Cardiac Insulin-Like Growth Factor 1 Receptor Signaling to Promote Health and Longevity.
38. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis
39. Targeting the upregulation of reactive oxygen species subsequent to hyperglycemia prevents type 1 diabetic cardiomyopathy in mice
40. Enhanced cardiac PI3Kα signalling mitigates arrhythmogenic electrical remodelling in pathological hypertrophy and heart failure
41. Homeostatic regulation of electrical excitability in physiological cardiac hypertrophy
42. Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategies
43. TLR2 ligands induce cardioprotection against ischaemia/reperfusion injury through a PI3K/Akt-dependent mechanism
44. Cardiac-Specific IGF-1 Receptor Transgenic Expression Protects Against Cardiac Fibrosis and Diastolic Dysfunction in a Mouse Model of Diabetic Cardiomyopathy
45. Attenuation of cardiac hypertrophy by inhibiting both mTOR and NFκB activation in vivo
46. Lipopolysaccharide-induced myocardial protection against ischaemia/reperfusion injury is mediated through a PI3K/Akt-dependent mechanism
47. PROMOTING PHYSIOLOGICAL HYPERTROPHY IN THE FAILING HEART
48. ROLE OF INSULIN-LIKE GROWTH FACTOR 1 AND PHOSPHOINOSITIDE 3-KINASE IN A SETTING OF HEART DISEASE
49. DIFFERENCES BETWEEN PATHOLOGICAL AND PHYSIOLOGICAL CARDIAC HYPERTROPHY: NOVEL THERAPEUTIC STRATEGIES TO TREAT HEART FAILURE
50. A mouse model of cardiac rhabdomyoma generated by loss of Tsc1 in ventricular myocytes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.